GLP‑1 receptor agonists and their dental implications: A practical guide for dental practitioners (Review)
Open Access
- 7 October 2026
- journal article
- Published by Spandidos Publications in World Academy of Sciences Journal
- Vol. 8 (6) , 1-10
Abstract
Glucagon‑like peptide‑1 receptor agonists (GLP‑1RAs) have revolutionized the management of type 2 diabetes mellitus and obesity. Their rapidly increasing use has critical implications for dental practice, yet guidance for clinicians remains limited. The aim of the present review was to provide an evidence‑based narrative summary of the oral and dental implications of GLP‑1RA therapy and to provide practical chair‑side recommendations for dental practitioners. For this purpose, a narrative literature review was performed to synthesize current evidence concerning the oral, periodontal and perioperative implications of GLP‑1RAs in dental practice. The PubMed/MEDLINE, Scopus, Web of Science and Google Scholar databases were searched for publications from January, 2015 through June, 2026. As this was a narrative review, studies were selected according to their clinical relevance and contribution to the mechanistic and practical questions addressed rather than according to a predefined systematic review protocol. No PRISMA flow diagram or quantitative study‑selection estimates were therefore applied. Particular emphasis was placed on distinguishing established clinical evidence from observational associations, preclinical findings and mechanistic hypotheses. Current evidence suggests that GLP‑1RAs may contribute to xerostomia, dysgeusia, halitosis and dental erosion, largely secondary to adverse gastrointestinal effects and salivary alterations. Conversely, improved glycemic control may favor periodontal health and wound healing. Delayed gastric emptying has critical implications for dental procedures requiring sedation or general anesthesia and necessitates careful preoperative assessment and interdisciplinary communication. On the whole, as the number of prescriptions of GLP‑1RAs continues to expand, dental practitioners should routinely identify affected patients, recognize potential oral manifestations, implement preventive strategies and consider perioperative implications to optimize patient safety and clinical outcomes.Keywords
This publication has 40 references indexed in Scilit:
- GLP‐1 receptor agonists: Bridging diabetes, obesity, and periodontitis—A scoping review of emerging evidenceJournal of Periodontology, 2026
- Evaluation of safety of preoperative GLP-1 receptor agonists in patients undergoing elective surgery: a systematic review, meta-analysis and meta-regressioneClinicalMedicine, 2025
- Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statementBritish Journal of Anaesthesia, 2025
- Glucagon-like peptide-1 receptor agonist use and the risk of residual gastric contents and aspiration in patients undergoing GI endoscopy: a systematic review and a meta-analysisGastrointestinal Endoscopy, 2024
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1Cell Metabolism, 2018
- A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VIDrugs in R&D, 2016
- Consensus report of the European Federation of Conservative Dentistry: erosive tooth wear—diagnosis and managementClinical Oral Investigations, 2015
- The functions of human saliva: A review sponsored by the World Workshop on Oral Medicine VIArchives of Oral Biology, 2015
- Periodontitis and diabetes: a two-way relationshipDiabetologia, 2011
- Effect of GLP-1 Treatment on Bone Turnover in Normal, Type 2 Diabetic, and Insulin-Resistant StatesCalcified Tissue International, 2009